Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Period:
Draw Mode:
| Volume | 0 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Telomir Pharmaceuticals Inc | TELO | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 6.62 | 04:09:37 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 6.62 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 0 | 0 | - | 4.76 - 20.72 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| - | 0 | $ 6.62 | USD |
Telomir Pharmaceuticals Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 196.02M | 29.61M | - | 0 | -13.07M | -0.44 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Telomir Pharmaceuticals News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TELO Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 5.95 | 7.52 | 5.90 | 6.95 | 20,860 | 0.67 | 11.26% |
| 1 Month | 5.48 | 9.39 | 5.283 | 7.77 | 58,008 | 1.14 | 20.80% |
| 3 Months | 7.00 | 20.72 | 4.76 | 8.26 | 67,899 | -0.38 | -5.43% |
| 6 Months | 7.00 | 20.72 | 4.76 | 8.26 | 67,899 | -0.38 | -5.43% |
| 1 Year | 7.00 | 20.72 | 4.76 | 8.26 | 67,899 | -0.38 | -5.43% |
| 3 Years | 7.00 | 20.72 | 4.76 | 8.26 | 67,899 | -0.38 | -5.43% |
| 5 Years | 7.00 | 20.72 | 4.76 | 8.26 | 67,899 | -0.38 | -5.43% |
Telomir Pharmaceuticals Description
| Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company focused on the development and commercialization of TELOMIR-1, a novel small molecule being developed to function as an oralin situtherapeutic treatment for human stem cells. Its goal is to develop and commercialize new treatment options for age-related inflammatory conditions, with hemochromatosis as its initial clinical focus, and to thereafter expand the development of TELOMIR-1 to post-chemotherapy recovery as well as a broader range of other age-related inflammatory diseases and conditions such as osteoarthritis. |
